【摘要】 胰高血糖素样肽(GLP)-1受体是2型糖尿病及其他代谢性疾病治疗中的重要靶点。目前已有多个GLP-1受体激动剂获批应用于临床，但传统的单受体药物常存在疗效不充分、不良反应较大等缺点，基于GLP-1的多受体激动剂往往能提升药效、减小不良反应，故受到广泛关注。本文根据作用受体差异对基于GLP-1的多受体激动剂进行分类，综述基于GLP-1的双受体和三受体激动剂的研究进展，旨在为该类药物的临床应用提供参考。更多还原

【Abstract】 Glucagon-like peptide( GLP)-1 receptor is an important target in the treatment of type 2 diabetes mellitus and other metabolic diseases. At present,GLP-1 receptor agonists have been clinically approved. However,traditional mono-receptor drugs suffer from limited efficacy and side effects. Multi-receptor agonists based on GLP-1 could further enhance efficacy and reduce side effects,thus attracting extensive attention. This review classifies multireceptor agonists based on GLP-1 according to the differences in targets,and summarizes the research progress of dualand triple-receptor agonists based on GLP-1 in order to provide references for clinical application of these drugs.更多还原